SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy
Taken together, MM patients under Lena therapy exhibit weakened antibody production but present a robust T cell response following SARS-COV-2 infection or vaccination. Our results highlight the importance of vaccination in this subgroup and moreover, argue against a Lena intake break around the time of vaccination.
Authors
- Ioana Martac
- Beate Preuß (ORCID: https://orcid.org/0009-0009-9505-707X)
- Reinhild Klein (ORCID: https://orcid.org/0000-0002-6111-3901)
- Luca Hensen (ORCID: https://orcid.org/0000-0001-8467-8537)
- Aileen Schenk
- Gülderen Yanıkkaya Demirel (ORCID: https://orcid.org/0000-0001-5775-491X)
- Britta Besemer
- Anna Stanger
- Claus‐Philipp Maier (ORCID: https://orcid.org/0000-0001-5299-3460)
- Sina Alexandra Beer (ORCID: https://orcid.org/0009-0004-0609-2644)
- Claudia Lengerke (ORCID: https://orcid.org/0000-0001-5442-2805)
- Osama Ahmad
Institutions
- University Children's Hospital Tübingen (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.3389/fimmu.2024.1510942
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Deutsche Forschungsgemeinschaft
- Eberhard Karls Universität Tübingen